NCT01635296View on ClinicalTrials.gov

A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Myelogenous Leukemia, Acute
Interventions
DRUG

RO5045377

Multiple escalating oral doses, Days 1 to 10 of each 28-day cycle

DRUG

RO5045377

Multiple escalating oral doses, Days 1 to 5 of each 28-day cycle

DRUG

cytarabine

20 mg/m2 sc, Days 1 to 10 of each 28-day cycle

DRUG

cytarabine

1 gm/m2 iv, Days 1 to 6 of each 28-day cycle

Trial Locations (9)

10595

Valhalla

13273

Marseille

19107

Philadelphia

40138

Bologna

78229

San Antonio

M5G 2M9

Toronto

H3T 1E2

Montreal

G12 0YN

Glasgow

M204BX

Manchester

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01635296 - A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia | Biotech Hunter | Biotech Hunter